Last reviewed · How we verify
Oral [14C] PF-06821497 (oral-14c-pf-06821497)
Oral [14C] PF-06821497 (generic name: oral-14c-pf-06821497) is a Unknown drug developed by Pfizer. It is currently FDA-approved for Systemic lupus erythematosus.
5-7 sentence executive brief for pharma professionals — oral-14c-pf-06821497, Pfizer Inc., mechanism not specified, systemic lupus erythematosus, no clinical differentiation, significant commercial revenue, no pipeline developments
At a glance
| Generic name | oral-14c-pf-06821497 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Systemic lupus erythematosus
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A4 substrates
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral [14C] PF-06821497 CI brief — competitive landscape report
- Oral [14C] PF-06821497 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Oral [14C] PF-06821497
What is Oral [14C] PF-06821497?
Oral [14C] PF-06821497 (oral-14c-pf-06821497) is a Unknown drug developed by Pfizer, indicated for Systemic lupus erythematosus.
What is Oral [14C] PF-06821497 used for?
Oral [14C] PF-06821497 is indicated for Systemic lupus erythematosus.
Who makes Oral [14C] PF-06821497?
Oral [14C] PF-06821497 is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of Oral [14C] PF-06821497?
oral-14c-pf-06821497 is the generic (nonproprietary) name of Oral [14C] PF-06821497.
What drug class is Oral [14C] PF-06821497 in?
Oral [14C] PF-06821497 belongs to the Unknown class. See all Unknown drugs at /class/unknown.
What development phase is Oral [14C] PF-06821497 in?
Oral [14C] PF-06821497 is FDA-approved (marketed).
What does Oral [14C] PF-06821497 target?
Oral [14C] PF-06821497 targets Unknown and is a Unknown.
Related
- Drug class: All Unknown drugs
- Target: All drugs targeting Unknown
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Systemic lupus erythematosus
- Compare: Oral [14C] PF-06821497 vs similar drugs
- Pricing: Oral [14C] PF-06821497 cost, discount & access